Can Exosomes Help With Erectile Dysfunction? What the Research Says

Erectile dysfunction is often thought of primarily as a blood-flow problem.

But the biology behind an erection is considerably more complicated.

Normal erectile function depends on coordinated communication between nerves, blood vessels, endothelial cells and smooth muscle within the penis. Conditions that disrupt those systems—including diabetes, vascular disease and nerve injury—can contribute to erectile dysfunction.

That complexity has made erectile dysfunction an emerging area of extracellular-vesicle and exosome research.

Scientists are investigating whether the biological signals carried by extracellular vesicles may influence several processes involved in erectile function, including vascular signaling, nitric-oxide pathways, smooth-muscle biology, fibrosis, oxidative stress and nerve repair. A 2024 review in Sexual Medicine Reviews describes a growing body of experimental EV research across different sources and mechanisms.

More recently, researchers combined the available animal studies in a 2025 meta-analysis.

The analysis included 20 studies involving 324 rats and reported favorable pooled findings not only for erectile-function measurements, but also for neural, vascular and smooth-muscle markers within erectile tissue.

So what exactly is the research finding?

What Does the Research Show?

The first thing to understand is that erectile dysfunction is not one biological condition.

Researchers have investigated EVs in experimental models involving:

• diabetes-related erectile dysfunction
• cavernous-nerve injury
• aging
• arterial injury
• chronic intermittent hypoxia
• Peyronie's disease

The two most extensively studied categories have been diabetic ED and cavernous-nerve-injury ED.

That's important because the underlying problem can differ.

Diabetes may affect endothelial function, circulation, oxidative stress, nerves and smooth muscle over time.

Cavernous-nerve injury, on the other hand, can directly disrupt the neurological signaling necessary for an erection and can produce secondary changes within erectile tissue. For related background on nerve biology, see what the research says about exosomes, nerve damage and neuropathy.

Researchers are therefore interested in EVs partly because extracellular vesicles can carry biologically active molecules involved in communication between cells.

Instead of looking at only one pathway, investigators have examined changes involving nerves, vascular endothelium, smooth muscle, collagen and nitric-oxide signaling.

Why Are Extracellular Vesicles Being Studied for Erectile Dysfunction?

An erection requires a coordinated neurovascular response.

Neural signals help trigger nitric-oxide production.

Nitric oxide contributes to relaxation of smooth muscle within erectile tissue.

That relaxation allows increased blood flow and expansion of the corporal tissue.

Researchers studying erectile dysfunction therefore commonly examine biological markers such as:

• neuronal nitric oxide synthase, or nNOS
• endothelial nitric oxide synthase, or eNOS
• smooth-muscle content
• endothelial markers
• collagen deposition
• apoptosis
• nerve integrity

They also use a physiological measurement known as the intracavernosal-pressure-to-mean-arterial-pressure ratio, or ICP/MAP.

In animal research, investigators electrically stimulate the cavernous nerve and measure the pressure response within the penis relative to systemic blood pressure.

It gives researchers a functional measurement rather than relying only on what tissue looks like under a microscope.

And across the existing EV literature, both functional and structural changes have been reported.

Research Highlight: 2025 Meta-Analysis of 20 Studies

Lou et al., 2025 — Stem Cell Research & Therapy

One of the strongest overviews of this field was published in 2025.

Researchers systematically searched PubMed, Embase, the Cochrane Library and Web of Science for studies published through December 2024.

They ultimately included 20 studies involving 324 rats.

The studies didn't all use the same extracellular-vesicle preparation.

Sources included several different cell populations, including mesenchymal stem/stromal cells, adipose-derived stem cells, bone-marrow-derived cells, urinary stem cells, corpus-cavernosum smooth-muscle cells, muscle-derived stem cells and pericytes.

That diversity is important.

It means the meta-analysis was examining a research category, not one standardized exosome product. For more on why that distinction matters, see where do exosomes come from?

What did researchers find?

Across the studies, extracellular-vesicle treatment was associated with a substantial pooled improvement in ICP/MAP compared with controls.

The standardized mean difference was:

SMD 4.19 — 95% CI 3.31–5.08

The analysis also reported favorable pooled changes in several tissue and molecular measurements.

Neuronal nitric oxide synthase

nNOS was higher in EV-treated animals:

SMD 4.18 — 95% CI 2.63–5.73

Endothelial nitric oxide synthase

eNOS was also higher:

SMD 2.83 — 95% CI 1.57–4.10

Smooth muscle

Alpha-smooth-muscle-actin measurements favored EV-treated animals:

SMD 5.33 — 95% CI 4.12–6.54

Smooth muscle-to-collagen ratio

Researchers also reported an increased smooth-muscle-to-collagen ratio:

SMD 3.40 — 95% CI 2.57–4.23.

Taken together, those measurements are interesting because the findings weren't limited to a single laboratory marker.

Researchers observed differences involving functional erectile response, neural signaling, endothelial biology and tissue structure.

The authors also reported substantial statistical heterogeneity between studies (I² values of roughly 74–86% across the pooled outcomes), funnel-plot asymmetry and a significant Egger's test indicating publication bias, although trim-and-fill adjustment left the pooled results in the same direction. Under the authors' nine-point scoring system, 13 of the 20 studies were rated high quality and 7 moderate quality, and follow-up after injection ranged from 2 to 8 weeks. This was animal research, not human clinical evidence.

Did the EV Source Make a Difference?

The researchers performed subgroup analyses comparing different EV sources.

For ICP/MAP, they found no statistically significant difference between MSC-derived EVs and adipose-derived-stem-cell EVs.

They likewise reported no significant subgroup difference for nNOS, alpha-SMA or the smooth-muscle-to-collagen ratio.

That does not establish that all EV preparations are equivalent. Source, manufacturing and characterization still differ between preparations — see how to evaluate an exosome product.

The subgroup comparison involved a relatively small collection of animal experiments using different protocols.

Source is only one characteristic of an EV preparation.

Manufacturing, cell culture, passage number, isolation, characterization, particle concentration, molecular cargo, formulation, storage and administration can also differ. See exosome concentration and particle count for one example of how preparations are quantified.

So these results shouldn't be interpreted to mean:

“All exosomes work the same.”

They simply mean the meta-analysis did not detect a statistically significant difference between those source categories for the outcomes it compared.

What About Diabetes vs. Nerve Injury?

The meta-analysis also compared diabetic ED models with cavernous-nerve-injury models.

Again, researchers did not find statistically significant subgroup differences in several major outcomes, including ICP/MAP, nNOS, alpha-SMA and smooth-muscle-to-collagen ratio.

That's an interesting finding because diabetes-related erectile dysfunction and nerve-injury-related erectile dysfunction arise through different biological pathways.

But it does not mean the conditions are interchangeable.

It means favorable EV-associated findings were observed across more than one experimental model.

Research Highlight: Cavernous Nerve Injury

Ouyang et al., 2018 — Stem Cell Research & Therapy

One of the earlier studies investigated MSC-derived exosomes in rats after bilateral cavernous-nerve injury.

Researchers isolated mesenchymal stem cells from rat bone marrow and collected exosomes from MSC culture supernatant using ultracentrifugation.

Thirty-two male Sprague-Dawley rats were divided among four groups:

• sham surgery
• nerve injury + PBS
• nerve injury + MSCs
• nerve injury + MSC-derived exosomes

Treatments were delivered by intracavernosal injection. Four weeks after the injury and administration, researchers electrically stimulated the cavernous nerve and measured erectile function.

What did they report?

The MSC-exosome group demonstrated improved erectile-function measurements compared with the untreated nerve-injury group.

Researchers also reported:

• increased smooth-muscle content
• increased neuronal nitric oxide synthase
• improved smooth-muscle-to-collagen ratio
• increased corpus-cavernosum smooth-muscle-cell viability
• reduced caspase-3 expression

The investigators interpreted their findings as evidence that reducing smooth-muscle-cell apoptosis may be one mechanism contributing to the observed changes.

Interestingly, the researchers reported effects similar in magnitude to the MSC-treated group in this experimental model.

What is the important limitation?

These were rats with experimentally induced cavernous-nerve injuries.

They were not men with erectile dysfunction.

And the EV preparation came from cultured rat bone-marrow MSCs.

This was an animal experiment using cultured-cell-derived exosomes, not a human clinical study. It therefore provides mechanistic and preclinical evidence, not proof that exosomes improve erectile function in people.

What Happens After Cavernous Nerve Injury?

Cavernous nerves play a major role in initiating the erectile response.

When those nerves are damaged, researchers have observed downstream changes involving:

• nitric-oxide signaling
• smooth-muscle loss
• apoptosis
• fibrosis
• endothelial function
• neural integrity

That's why cavernous-nerve-injury models have become common in regenerative-medicine research.

Another study, published in Andrology in 2018, compared extracellular vesicles derived from adipose-derived MSCs and bone-marrow-derived MSCs in rats with bilateral cavernous-nerve injury.

Researchers reported significantly higher ICP/MAP measurements in both EV-treated groups compared with injured controls.

They also reported favorable changes involving nNOS, endothelial markers, alpha-SMA, neurofilament and smooth-muscle-to-collagen measurements.

Again, this was animal research.

But it provides another example in which researchers observed changes involving both erectile function and the underlying neural/vascular tissue environment.

Does Repeated Administration Matter?

Researchers are also beginning to ask questions beyond simply whether EVs produce an experimental effect.

One of those questions is whether administration frequency matters.

A study published in 2024 compared single and repeated administrations of MSC-derived exosomes in rats with bilateral cavernous-nerve injury.

The researchers isolated MSC-derived exosomes using an aqueous two-phase system and divided animals into normal, nerve-injury, single-administration and repeat-administration groups.

Both EV groups demonstrated significantly higher ICP/MAP measurements than untreated injured animals.

The researchers also used RNA sequencing and laboratory endothelial-cell experiments to investigate potential molecular mechanisms.

Studies like this represent an important evolution of the field.

Once researchers observe a biological signal, the next questions become:

Which preparation?

How much?

How often?

For which underlying cause of erectile dysfunction?

Those questions remain unresolved. This was a rat study, and it does not establish an administration schedule for people.

What About Diabetic Erectile Dysfunction?

Diabetes can affect erectile function through several interconnected pathways.

Chronic metabolic disease may influence:

• endothelial function
• nitric-oxide signaling
• peripheral nerves
• oxidative stress
• smooth muscle
• fibrosis
• microvascular circulation

That makes diabetic ED biologically different from a traumatic cavernous-nerve injury.

Nevertheless, diabetic models make up a substantial portion of the EV literature.

Of the 20 studies in the 2025 meta-analysis, eight used diabetic rat models, while seven used cavernous-nerve-injury models.

The pooled research suggests that investigators aren't merely measuring whether an animal achieves a greater pressure response.

They're studying whether EV-associated biological changes occur in the vascular and structural systems involved in erectile function.

Another 2023 Systematic Review Reached Similar Conclusions

The 2025 analysis wasn't the first attempt to combine this research.

A systematic review and meta-analysis published in Sexual Medicine screened 146 retrieved studies and evaluated 11 eligible preclinical studies.

Its pooled analysis likewise reported favorable findings for ICP/MAP (SMD 3.68, 95% CI 2.64–4.72) and structural markers including smooth-muscle-to-collagen ratio, alpha-SMA, CD31, nNOS, eNOS, TGF-β1 and caspase-3.

That matters because the positive direction of the preclinical literature isn't dependent on one individual experiment.

Multiple research groups using different models and EV preparations have reported related findings, and more than one systematic analysis has identified an overall positive signal — all of it preclinical.

But there is still a major gap.

Where Is the Human Research?

This is where the evidence changes substantially.

Despite the encouraging animal research, human clinical evidence remains limited.

A 2024 review in Sexual Medicine Reviews described the EV field as providing a foundation for further investigation and potential clinical application—not as an established human treatment.

The 2025 meta-analysis likewise explicitly called for clinical translation and larger human studies.

There is, however, an important development underway.

A Human Placebo-Controlled Trial Is Registered

A Phase 2 clinical study registered with ClinicalTrials.gov (NCT07319533) is designed to investigate MSC-derived exosomes in men with moderate-to-severe erectile dysfunction.

The planned study includes 70 participants, with 35 assigned to each arm.

Researchers intend to compare:

human umbilical-cord-MSC-derived exosomes

against:

0.9% saline placebo.

Participants are planned to receive six weekly intracavernosal administrations, with outcomes including IIEF-5 score, Erectile Hardness Score and Doppler measurements of penile blood flow.

As of the current ClinicalTrials.gov record, however, the study is listed as not yet recruiting, with no clinical results posted.

That's an important distinction.

A registered clinical trial tells us that researchers are taking the question into human investigation.

It does not tell us what the answer will be.

We should therefore not count this study as evidence that exosomes improve erectile dysfunction in men.

What it does show is where the field is heading next.

Why Nitric Oxide Keeps Appearing in the Research

One recurring finding in the ED literature involves nitric-oxide synthase.

Both nNOS and eNOS contribute to pathways involved in normal erectile physiology.

Across the 2025 meta-analysis, EV-treated animals demonstrated higher pooled measurements of both nNOS and eNOS compared with controls.

Individual studies have also reported similar changes.

Researchers are therefore investigating whether EV cargo influences signaling pathways involved in endothelial function and neuronal communication.

But the important point isn't simply that an EV contains a particular molecule.

The biological effect of an extracellular-vesicle preparation depends on what the vesicles actually carry and how recipient cells respond.

That brings us back to a recurring theme throughout exosome research.

“Exosomes” Are Not One Standardized Substance

The 20 studies in the 2025 meta-analysis used EVs derived from numerous cellular sources.

They also used different experimental models, isolation methods and research protocols.

Even the authors highlighted batch-to-batch variability and lack of standardized large-scale manufacturing protocols as barriers to clinical translation. How a preparation is measured and documented is part of that picture — see extracellular vesicle characterization and testing.

So asking:

“Do exosomes work for erectile dysfunction?”

is actually an oversimplification.

A scientifically better question is:

“Which extracellular-vesicle preparation was studied, how was it produced and characterized, what biological model was tested, and what outcomes were measured?”

Those distinctions become increasingly important as EV research moves toward human trials.

What Does the Research Not Establish?

The current literature does not establish that commercially available exosome products treat erectile dysfunction.

It does not establish an appropriate human:

• particle concentration
• dose
• administration frequency
• treatment schedule
• EV source
• formulation

It also doesn't establish that results from intracavernosal administration in experimental animals can be generalized to other methods of administration.

And the animal studies don't tell us whether a man with diabetic ED, vascular ED, post-surgical nerve injury, age-related erectile dysfunction or psychologically mediated ED would respond in the same way.

Those are questions human clinical trials need to answer.

Why Results May Vary

As with many biologically active interventions, people may not respond identically. Individual genetics, age, underlying biology, disease severity and other person-specific factors may influence biological responses. The extracellular-vesicle preparation itself—including its source, manufacturing, characterization and formulation—may also matter. Researchers are still working to understand which factors may help predict how individuals respond.

Erectile dysfunction adds another layer of variability because it can arise from very different underlying causes.

For one person, vascular disease may dominate.

For another, diabetes-related nerve and endothelial dysfunction may contribute.

Another person may have cavernous-nerve injury following pelvic surgery.

Psychological factors, medications, hormonal abnormalities and other health conditions can also affect erectile function.

That means future EV research will need to determine not merely whether an average group responds, but which biological forms of erectile dysfunction may be most relevant to particular EV approaches.

The Bottom Line

Extracellular-vesicle research in erectile dysfunction has produced a surprisingly consistent body of preclinical evidence.

A 2025 meta-analysis combining 20 studies and 324 rats reported favorable pooled findings for erectile-function measurements along with changes involving neuronal and endothelial nitric-oxide synthase, smooth muscle and smooth-muscle-to-collagen ratio.

Earlier individual experiments and a separate systematic review have reported findings in the same general direction.

Researchers are also moving beyond simply asking whether EVs produce an effect.

They're investigating:

• different EV sources
• diabetic versus nerve-injury models
• repeated administration
• molecular cargo
• neural mechanisms
• vascular mechanisms
• fibrosis
• smooth-muscle preservation

That's the encouraging part.

The major unanswered question is human translation.

At present, the evidence base is dominated by animal research. A placebo-controlled Phase 2 human study has been registered, but it has not yet produced clinical results.

So the research supports continued investigation—not a conclusion that exosomes have been clinically established as a treatment for erectile dysfunction.